CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
March 31, 2021 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional...
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
February 23, 2021 08:00 ET
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
November 06, 2020 08:00 ET
|
Cocrystal Pharma, Inc.
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
Cocrystal Pharma Provides Update on Influenza A Program
October 19, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...
Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
October 02, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District...
Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 08, 2020 08:00 ET
|
Cocrystal Pharma, Inc.
– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT – BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
August 26, 2020 22:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces $10.0 Million Bought Deal Offering
August 26, 2020 17:35 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
August 06, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
February 27, 2020 07:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...